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Aim and METHODS: The aim of this health technology
assessment was to analyse the current scientiﬁc and
genetic counselling situation about predictive genetic
testing for hereditary breast and colorectal cancer. This
report is based on a systematic literature research and on
a speciﬁc health technology assessment (CCOHTA) resp.
review (American Gastroenterological Ass.). Background:
Breast and colorectal cancer are counted among the most
frequently cancer diseases. 5–10% show a familial deter-
mination. A hereditary modiﬁed gen is responsible for the
increased cancer risk. Results and CONCLUSION: The
identiﬁcation of the responsible gen defect in an affected
family member is important. If the test result is positive
there is an uncertainty about if the desease will occur,
when and in which degree founded in the geno-/pheno-
type correlation. The individual risk estimation is based
upon empirical evidences. The so-called preventive
medical check ups are early detection examinations. For
colorectal cancer the evidence about early detection
methods is better than for breast cancer. Prophylactic
mastectomy (PM) reduces the relativ breast cancer risk by
approxemately 90%. Colectomy can be used as a pro-
phylactic (FAP) and therapeutic method. After operations
the cancer risk remains high and so early detection exem-
inations are still necessary. The evidence is often frag-
mentary and from limited qualit. New identiﬁcations of
mutations and demand creation will result in an increase
of predictive genetic counselling and testing. There is a
gap between predicitve genetic diagnosis and the predic-
tion, prevention, early detection and surgical interven-
tions. Since predictive genetic diagnosis is a very sensitive
issue it is important to deal carefully with it in order to
avoid inappropriate hopes.
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SELF-REPORTED PATIENT EXPERIENCE DATA,
PROVIDED TO PHYSICIANS AT THE POINT-OF-
CARE, OFFER AN IMPORTANT COMPLEMENT
TO TRADITIONAL EFFICACY DATA AND
ENABLE THE DERIVATION OF PRACTICE-WIDE
TREATMENT GUIDELINES
Schmeichel CJ1, Netherton DR2
1SMA, Munster, IN, USA; 2InfoMedics International, Inc,
Woburn, MA, USA
OBJECTIVES: Prospective “real-world” patient experi-
ence data is a highly acceptable form of data that can be
relevant to an individual clinician’s practice in determin-
ing the optimal patient proﬁle to achieve the most efﬁca-
cious results. This study was designed to assess the
real-world effectiveness of a sleeping medication and
provide the treating physician with self-reported data to
proﬁle optimal patients for treatment. METHODS: Self-
reported data about symptoms of transient insomnia and
symptom relief prior to and after using a sleeping med-
ication were collected from patients via telephone or the
Internet. Treating physicians enrolled all patients and
received individual patient reports. RESULTS: A total of
1378 patients completed both surveys. Ages were 39% <
45 and 43% between 45 and 64, and 77% were female.
At baseline, 62% of patients reported having difﬁculty
sleeping >14 nights per month. Factors creating periods
of insomnia included stress (59%), depression/anxiety
(39%), travel (3%), and work-related issues (3%). The
most important quality in a sleeping medication was
reported to be absence of “grogginess” the following day
(46%). The time required to get to sleep (15 to 60
minutes) improved for all study participants. With a sta-
tistical signiﬁcance of p < 0.001, reported symptoms of
trouble falling asleep, not feeling rested, feeling sleepy the
next day, and trouble functioning the next day were
improved by 3 to 5 points on a 10-point scale. CON-
CLUSIONS: Findings suggest that the use of the study
medication offers considerable relief of key symptoms.
The ﬁndings also provide the practicing clinician with
insights into the factors that patients require in a sleep-
ing medication and suggest that effectiveness endpoints
complement and even synergize with efﬁcacy endpoints.
METHODOLOGICAL ISSUES—Cost Studies
PMD12
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POSTERS PRESENTED AT THE 7TH ANNUAL
INTERNATIONAL ISPOR MEETING
Kwon S,Taylor MD, Mayhew D, Hartzema AG
University of Florida, Gainesville, FL, USA
OBJECTIVE: Pharmaceconomic studies evaluate medica-
tions in terms of ﬁnancial consequences. Thus, the valid-
ity of the source of cost data inﬂuences study results. The
primary objective of this study was to examine the
sources of cost data used in studies presented as posters
at the 7th Annual International ISPOR Meeting. Type of
analysis and perspective of studies were also assessed.
METHODS: The abstract of economic outcomes studies
printed in Value in Health for each poster and a handout
of the poster, when available, were used to assess the
source of cost data, analysis type, and perspective. Three
reviewers working together extracted and categorized the
information for each poster presented. A 20% random
sample of studies was reassessed to evaluate the reliabil-
ity of data extraction and categorization. RESULTS: Of
127 studies sub-classiﬁed as economic within the various
disease categories, 19 studies were excluded from the
analysis due to not meeting inclusion and exclusion 
criteria. Sources of cost data were classiﬁed into 12 
categories. The 4 most frequently used sources being lit-
erature (17%), commercial databases (13%), government
databases (13%), and national statistics (11%). The dis-
tribution of study types was: cost-effectiveness (27%),
cost-utility (3%), cost beneﬁt (2%), cost minimization
(2%), cost of illness (2%), cost assessment (62%), and
multiple (3%). The analytic perspective was clearly stated
in only 54% of studies. CONCLUSIONS: Pharmacoeco-
nomic evaluations play an important role in Health care
decision-making. The source and perspective of cost data,
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the focus of this study, are key pieces of information nec-
essary for decision-makers in evaluating economic out-
comes study ﬁndings. This analysis suggests the need for
continued emphasis of guidelines calling for clear identi-
ﬁcation of the source and perspective of cost data.
PMD13
PMD14
WILLINGNESS TO PAY,WILLINGNESS TO WAIT,
AND SUPER QALYS: NARROWING THE
CONCEPTUAL GAP BETWEEN CARDINAL AND
ORDINAL HEALTH UTILITY MEASURES
Johnson FR1, Hauber AB2, Mauskopf J1
1Research Triangle Institute, Research Triangle Park, NC, USA;
2Research Triangle Institute, Hatboro, PA, USA
OBJECTIVES: Using (SG) or time tradeoff (TTO) mea-
sures of QALY utility weights requires strong and gener-
ally unrealistic assumptions that effectively break the link
between SG and TTO utilities and utility-theoretic pref-
erences. In particular, QALY linearity assumptions violate
the generally accepted law of diminishing marginal utility.
This presentation derives general “super QALYs” from
nonlinear, ordinal utility functions that incorporate
wealth and non-health utility variables as well as time in
speciﬁc health states. Thus super QALYs can incorporate
patient satisfaction related to dosage or drug administra-
tion and other utility-relevant factors for both acute and
chronic health outcomes. METHODS: We illustrate com-
parisons between conventional QALY and super QALY
measures using linear and Cobb-Douglas utility func-
tions. Under general conditions, nonlinear super QALYs
may rank health outcomes differently than QALYs, but
linear super QALYs rank outcomes similarly. If prefer-
ences are nonlinear, marginal changes will be weighted
differently with QALYs and super QALYs, thus affecting
incremental cost-effectiveness ratios. When derived from
consistent utility-theoretic preference relations, super
QALYs, willingness to pay (WTP), and willingness to wait
(WTW) represent alternative and equivalent rescaling of
the same preference information. RESULTS: We explore
the empirical signiﬁcance of these conceptual results using
an empirical utility function from a recent choice-format
conjoint study of acute respiratory and cardio-vascular
symptoms. Setting utility to zero for the worst-observed
outcome, quality-adjusted life days (QALDs) range from
0.066 for 5 days of pneumonia symptoms requiring hos-
pitalization to 4.25 for 5 days of nasal congestion with
some physical activity restrictions. Corresponding WTP,
WTP per QALD, and WTW values for the same outcomes
are $980 and $30, $199 and $40, and 4.93 and 0.75,
respectively. CONCLUSIONS: Although nonlinear
ordinal utility functions sacriﬁce the simplicity of con-
stant QALY weights and linearity over time, improved
validity justiﬁes the modest increase in analytical burden
in many cases.
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THE INTERNATIONAL COSTING SOURCES
DATABASE: A TOOL FOR ENSURING
CONSISTENT AND RIGOROUS
INTERNATIONAL COSTING
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